NCT03873181View on ClinicalTrials.gov

Post-Market Evaluation of HEMOBLAST™ Bellows in Laparoscopic Abdominal, Gynecological, and Urological Surgery

CompletedOBSERVATIONAL

Enrollment

102

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

August 26, 2020

Study Completion Date

August 26, 2020

Conditions

Hemostasis

Interventions

DEVICE

HEMOBLAST™ Bellows

Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.

Trial Locations (8)

51109

Kliniken der Stadt Koln, Krankenhaus Merheim, Cologne

60487

Agaplesion Markus Krankenhaus, Frankfurt am Main

75674

Hôpital Saint Jospeh, Paris

Unknown

University Hospital Salzburg, Salzburg

Hôpital Beaujon, Clichy

CHU Grenoble, Grenoble

University Hospital Bonn, Bonn

Asklepios Klinik Barmbek, Hamburg

All Listed Sponsors

lead

Biom'Up France SAS

INDUSTRY

NCT03873181 - Post-Market Evaluation of HEMOBLAST™ Bellows in Laparoscopic Abdominal, Gynecological, and Urological Surgery | Biotech Hunter | Biotech Hunter